Britannia Life Sciences Balance Sheet Health
Financial Health criteria checks 0/6
Britannia Life Sciences has a total shareholder equity of CA$11.9M and total debt of CA$7.2M, which brings its debt-to-equity ratio to 60.4%. Its total assets and total liabilities are CA$23.0M and CA$11.1M respectively. Britannia Life Sciences's EBIT is CA$1.2M making its interest coverage ratio 1.1. It has cash and short-term investments of CA$1.7M.
Key information
60.4%
Debt to equity ratio
CA$7.19m
Debt
Interest coverage ratio | 1.1x |
Cash | CA$1.72m |
Equity | CA$11.90m |
Total liabilities | CA$11.06m |
Total assets | CA$22.96m |
Recent financial health updates
No updates
Recent updates
Britannia Life Sciences (CSE:BLAB) Shareholders Will Want The ROCE Trajectory To Continue
Mar 01Britannia Life Sciences (CSE:BLAB) Might Have The Makings Of A Multi-Bagger
Nov 14Returns At Britannia Life Sciences (CSE:BLAB) Appear To Be Weighed Down
Apr 19A Look At The Fair Value Of Britannia Life Sciences Inc. (CSE:BLAB)
Mar 13Financial Position Analysis
Short Term Liabilities: BLAB's short term assets (CA$3.1M) do not cover its short term liabilities (CA$5.6M).
Long Term Liabilities: BLAB's short term assets (CA$3.1M) do not cover its long term liabilities (CA$5.4M).
Debt to Equity History and Analysis
Debt Level: BLAB's net debt to equity ratio (46%) is considered high.
Reducing Debt: Insufficient data to determine if BLAB's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: BLAB's debt is not well covered by operating cash flow (19.9%).
Interest Coverage: BLAB's interest payments on its debt are not well covered by EBIT (1.1x coverage).